Novo Nordisk A/S is a Danish pharmaceutical company that specializes in the production and distribution of diabetes care and other related healthcare products. The company was founded in 1923 in Denmark by August Krogh and Harald Pedersen. Novo Nordisk is headquartered in Bagsværd, Denmark, and has operations in more than 80 countries worldwide.
Novo Nordisk is dedicated to improving the lives of people living with diabetes and other chronic conditions. The company's main focus is on developing innovative pharmaceuticals and medical devices for diabetes treatment. Their portfolio includes a wide range of products, including insulin, insulin analogs, and other injectable diabetes medications. Novo Nordisk also offers devices such as insulin pens and needles for diabetes management.
One of the company's most notable achievements is the discovery and production of the first insulin for clinical use. This breakthrough paved the way for the effective treatment of diabetes, saving countless lives and improving the quality of life for millions of people worldwide. Novo Nordisk's commitment to diabetes care has made it a global leader in the field.
Novo Nordisk's flagship product is its long-acting insulin analog called Levemir. Levemir provides a steady and prolonged release of insulin, helping to control blood sugar levels in people with diabetes. The company has also developed other insulin analogs, such as NovoRapid and NovoMix, which offer different profiles and options for diabetes management. These products have contributed significantly to the advancement of diabetes treatment and have become key offerings in Novo Nordisk's extensive portfolio of diabetes care solutions.
Novo Nordisk is listed on the NASDAQ OMX Copenhagen stock exchange in Denmark under the ticker symbol NOVO-B. The company has a strong presence in the global pharmaceutical market and has consistently ranked among the largest pharmaceutical companies in the world. It has subsidiaries and manufacturing facilities in various countries, enabling it to reach a broad customer base and supply its products globally.
In recent years, Novo Nordisk has expanded its focus beyond diabetes care to include other chronic diseases such as obesity, hemophilia, and growth disorders. The company invests heavily in research and development to develop new therapies and improve existing treatments for these conditions. Novo Nordisk's commitment to innovation and patient care has earned it a reputation as a trusted and reliable provider of healthcare solutions.